| SUNDAY 14 SEPTEMBER 2025 | |
|---|---|
| 17.00-18.00 | Registration |
| OPENING EU2CURE HIV SYMPOSIUM Chaired by: Linos Vandekerckhove and Sarah Gerlo |
|
| 18.00-18.30 | Opening ceremony Linos Vandekerckhove, Ghent University, Ghent, Belgium |
| 18.30-19.00 | Plenary I: Future directions for HIV cure research tbd |
| 19.00-19.30 | Plenary II: Clues for viral control in the HIV2000 cohort tbd |
| 19.30-21.00 | Opening reception |
| MONDAY 15 SEPTEMBER 2025 | |
|---|---|
| SESSION 1 - NUCLEAR IMPORT, HIV INTEGRATION AND TRANSCRIPTION Chaired by: tbc |
|
| 08.30-09.00 | Plenary III: The importance of HIV integration for HIV pathogenesis tbd |
| 09.00-09.25 | Passage of the HIV capsid cracks the nuclear pore tbd |
| 09.25-09.50 | Nuclear retention of unspliced HIV-1 RNA as a reversible post-transcriptional block in latency tbd |
| 09.50-10.10 | 2x 10’ Poster presentations tbd |
| 10.10-10.40 | Break |
| SESSION 2 - TISSUE AND CELLULAR LOCALIZATION OF THE VIRAL RESERVOIR Chaired by: tbc |
|
| 10.45-11.10 | BACH2-driven tissue resident memory programs promote HIV-1 persistence tbd |
| 11.10-11.35 | Is the central nervous system reservoir a hurdle for an HIV cure? tbd |
| 11.35-12.00 | A granular view on HIV DNA+ cells in lymph nodes tbd |
| 12.00-12.20 | 2x 10’ Poster presentations tbd |
| 12.20-12.40 | Round table tbd |
| 12.40-13.55 | Lunch and Postersession |
| SESSION 3 - VIRAL AND CELLULAR DRIVERS OF RESERVOIR SIZE AND REBOUND Chaired by: tbd |
|
| 14.00 - 14.25 | Identification of the origin of viral rebound using bar coded SIV tbd |
| 14.25-14.50 | PET CT guided tracking of viral reservoirs and viral rebound tbd |
| 14.50-15.15 | Taking a deep dive in the link of integration sites to viral rebound tbd |
| 15.15-15.35 | 2x 10’ Poster presentations tbd |
| 15.35-16.05 | Break |
| SESSION 4 - IMPLEMENTATION OF CURE RESEARCH IN AFRICA Chaired by: tbd |
|
| 16.05-16.30 | Evaluation of 2 bNAbs plus vesatolimod in early-treated South African women with HIV-1 during ATI tbd |
| 16.30-16.55 | Tbd tbd |
| 16.55-17.40 | Satellite session 1 |
| 17.40-18.10 | Plenary IV: Inspirational talk |
| TUESDAY 16 SEPTEMBER 2025 | |
|---|---|
| SESSION 5 - INTEGRATED ORGAN IMMUNITY Chaired by: tbd |
|
| 08.30-09.00 | Plenary V: Using systems immunology to unravel viral pathogenesis tbd |
| 09.00-09.25 | A chromatin-regulated biphasic circuit coordinates inflammation tbd |
| 09.25-09.50 | Augmenting innate immune responses to restrict the reservoir tbd |
| 09.50-10.10 | 2x 10’ Poster presentations tbd |
| 10.10-10.40 | Break |
| SESSION 6 - ADAPTIVE IMMUNE RESPONSE LINKED TO VIRAL CONTROL tbd |
|
| 10.45-11.10 | Enhanced detection of antigen-specific T cells as correlates of control tbd |
| 11.10-11.35 | Using systems serology to evaluate HIV responses and signatures of control tbd |
| 11.35-12.00 | TGF-β1 drives tissue-specific differentiation and function of resident NK cells tbd |
| 12.00-12.20 | 2x 10’ Poster presentations tbd |
| 12.20-13.35 | Lunch |
| SESSION 7 - EPIGNETIC CONTROL OF ADAPTIVE IMMUNITY AND EXHAUSTION Chaired by: tbd |
|
| 13.40-14.10 | Plenary VI: Epigenetic control of adaptive immunity and exhaustion tbd |
| 14.10-14.35 | Multi-Omic Atlas reveals cytotoxic phenotype and ROS-linked metabolic quiescence as key features of CTL-resistant HIV-infected CD4 + T-cells tbd |
| 14.35-15.00 | TBD tbd |
| 15.00-15.45 | Satellite session 2 |
| 15.45-16.05 | 2x 10’ Poster presentations tbd |
| 16.05-16.35 | Break |
| SESSION 8 – Improving antibody approaches for an HIV Cure? Chaired by: tbdo |
|
| 16.40-17.05 | Probabilities of developing HIV-1 bNAb sequence features in uninfected and chronically infected individuals tbd |
| 17.05-17.40 | ART-DEX: A novel strategy to monitor broadly neutralizing antibody activity during antiretroviral therapy of HIV-1 tbd |
| 17.40-18.00 | Round table discussion on host immunity and reservoir control |
| 19.00 - 22.00 | Speakers dinner |
| WEDNESDAY 17 SEPTEMBER 2025 | |
|---|---|
| SESSION 9 - CURE TRIALS IN HUMANS Chaired by: tbd |
|
| 08.30-08.55 | Recent results of the RIO study tbd |
| 08.55-09.20 | HIV GAG x CD3 soluble TCR bispecific reduces the active HIV reservoir in a Phase 1/2 trial tbd |
| 09.20-9.45 | Involving CAB in clinical trial design tbd |
| 09.45-10.05 | 2x 10’ Poster presentations tbd |
| 10.05-10.25 | Break |
| SESSION 10 - CLINICAL FACTORS CRITICAL FOR ATI Chaired by: tbd |
|
| 10.30-10.55 | Safety aspects in eClear and Titan tbd |
| 10.55-11.20 | Minimal clinical aspects important for ATI studies tbd |
| 11.20-11.45 | Patient related factors to consider during ATI's tbd |
| 11.45-12.15 | Roundtable on trial design and acceptability tbd |
| 12.15-12.25 | Prize for best poster presentations & closing remarks Linos Vandekerckhove, Ghent University, Ghent, Belgium |